There are over 200 distinct types of cancer, grouped into five major categories based on where in the body they start. But that number keeps growing. As genetic sequencing reveals molecular subtypes within each cancer, what once looked like a single disease often turns out to be several biologically different ones. The real count depends on whether you’re counting by organ, by tissue type, or by molecular profile.
The Five Major Categories
Every cancer falls into one of five broad groups, defined by the type of tissue where the disease originates.
Carcinomas start in epithelial tissue, the cells that line your skin, organs, and internal passageways like the digestive tract. This is by far the largest category, accounting for 80 to 90 percent of all cancer cases. Breast, lung, colorectal, and prostate cancers are all carcinomas.
Sarcomas arise in connective and supportive tissues: bones, cartilage, tendons, muscle, and fat. They’re far less common than carcinomas, and the tumors typically resemble the tissue they grow in.
Leukemias are cancers of the bone marrow, sometimes called “liquid cancers” because they involve the blood rather than forming solid tumors. The disease is linked to overproduction of immature white blood cells and can also affect red blood cells, leading to poor clotting and fatigue from anemia.
Lymphomas develop in the lymphatic system, the network of nodes, vessels, and organs (including the spleen, tonsils, and thymus) that produces infection-fighting white blood cells. Unlike leukemias, lymphomas are solid cancers. They split into two subcategories: Hodgkin lymphoma and non-Hodgkin lymphoma.
Myelomas originate in plasma cells within bone marrow. Plasma cells normally produce proteins found in your blood, so myeloma disrupts that process.
Why the Count Keeps Changing
The traditional way to classify cancer is by the organ where it starts: lung cancer, liver cancer, skin cancer. That approach gives you a list of roughly 200 types. But two people with “lung cancer” can have tumors that behave very differently at the molecular level, respond to different treatments, and carry different prognoses.
Advances in genomic and molecular profiling are splitting those 200-plus types into an expanding number of subtypes. Melanoma, for example, is now recognized as comprising biologically distinct subtypes rather than a single disease. Kidney cancer is being broken down through whole-genome sequencing and methylation analysis into finer histological subtypes. Biliary tract cancers, once grouped together, are being examined for potential molecular subtypes based on where exactly in the biliary system they occur. This pattern repeats across nearly every major cancer type, which is why no single definitive number exists.
The International Classification of Diseases for Oncology, maintained by the World Health Organization and used by cancer registries worldwide, assigns each tumor a five-digit morphology code that captures its specific histological type and behavior (malignant, benign, in situ, or uncertain). That coding system contains thousands of entries, reflecting just how granular cancer classification has become.
The Most Common Types
Despite the enormous variety, a handful of cancers account for most diagnoses. In 2022, the top 10 cancer types made up roughly two-thirds of all new cases and deaths globally. The five most common by new cases were:
- Lung cancer: 2.5 million new cases, 12.4% of the global total
- Female breast cancer: 2.3 million cases, 11.6%
- Colorectal cancer: 1.9 million cases, 9.6%
- Prostate cancer: 1.5 million cases, 7.3%
- Stomach cancer: 970,000 cases, 4.9%
Together, just these five types represented nearly half of all cancer diagnoses worldwide.
Common vs. Rare Cancers
The National Cancer Institute defines a rare cancer as one affecting fewer than 40,000 people per year in the United States. By that threshold, the majority of the 200-plus recognized cancer types are actually rare. Most people will only encounter a small number of common cancers in their lifetime, but the long tail of uncommon and ultra-rare types is vast.
All childhood cancers are considered rare by default because cancer rates in children are so low overall. Pediatric cancers also look fundamentally different from adult cancers. About 40% of childhood cancers are blood-related (leukemias and lymphomas), roughly 25% are central nervous system tumors, and the remaining 35% are other solid tumors. These childhood solid tumors tend to be embryonal in origin, a stark contrast to the epithelial carcinomas that dominate adult cancer. Even retinoblastoma, a rare eye tumor making up just 2% of childhood cancers, behaves differently from anything typically seen in adults.
What This Means in Practice
If someone tells you there are “over 200 types of cancer,” that’s a reasonable answer based on organ-level classification. If you count the molecular and genetic subtypes now being identified through tumor profiling, the number is considerably higher and still climbing. The shift toward molecular classification isn’t just academic. It’s changing how cancers are treated, because two tumors in the same organ with different molecular signatures may respond to completely different therapies.
For patients, the practical takeaway is that a cancer diagnosis today is far more specific than it was even a decade ago. A pathology report won’t just say “breast cancer” or “lung cancer.” It will typically include the histological subtype, molecular markers, and grade, all of which shape the treatment plan and expected outcomes.